Drug
Wockhardt’s Zaynich antibiotic gets CDSCO nod ahead of FDA review
Indicated for severe bacterial infections including dental abscesses; adult dosing 500 mg orally every 8 hr per label; approved by CDSCO on 27 May 2026 with FDA submission underway; marketed by Wockhardt in India; supports management of refractory oral and maxillofacial infections.
Source: Biotecnika
17 Nov 2026 · DentalSync AI — global BDS career platform